This proposal will explore genetic pathways that specify the commitment of embryonic mesoderm toward hematopoietic fate in model organisms like the fish and mouse, in order to identify mechanisms that can be engineered to drive hematopoietic stem cell differentiation from mouse and human embryonic stem cells. To date, we have succeeded in preliminary efforts to generate hematopoietic stem cells that, when modified by the homeotic selector gene hoxb4, engraft multi-lineage hematopoiesis in irradiated primary and secondary mice. Recent data from anemic zebrafish mutants has identified the cdx4 gene as a central player in specifying hematopoietic mesoderm through activation of hox genes. When expressed in embryonic stem cells, cdx4 stimulates hematopoiesis and in combination with hoxb4 promotes enhanced lymphoid-myeloid engraftment. We will test the hypothesis that cdx4 is an essential gene for specifying hematopoiesis in mouse embryos and embryonic stem cells. We will investigate whether cdx4, hoxb4, and the blood specification factor scl will induce hematopoietic differentiation if delivered by direct protein transduction, effectively testing the hypothesis that these factors act as developmental switches to specify blood fate. We will determine whether the embryonic morphogens Indian Hedgehog, Bone Morphogenetic Protein 4, and Wnt3a will instruct blood development and activate cdx-hox signaling in embryonic stem cells. Ultimately, we will test whether hematopoietic tissues derived from embryonic stem cells, including lines created by therapeutic cloning, parthenogenesis, and somatic cell reprogramming, can be harnessed to correct genetic bone marrow disorders in murine models. These studies will provide an important test of the feasibility of therapeutic applications of embryonic stem cells.

Agency
National Institute of Health (NIH)
Institute
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Type
Research Project (R01)
Project #
5R01DK070055-02
Application #
7061589
Study Section
Development - 1 Study Section (DEV)
Program Officer
Wright, Daniel G
Project Start
2005-05-15
Project End
2010-04-30
Budget Start
2006-05-01
Budget End
2007-04-30
Support Year
2
Fiscal Year
2006
Total Cost
$670,246
Indirect Cost
Name
Children's Hospital Boston
Department
Type
DUNS #
076593722
City
Boston
State
MA
Country
United States
Zip Code
02115
Lengerke, Claudia; Daley, George Q (2012) Caudal genes in blood development and leukemia. Ann N Y Acad Sci 1266:47-54
McKinney-Freeman, Shannon; Cahan, Patrick; Li, Hu et al. (2012) The transcriptional landscape of hematopoietic stem cell ontogeny. Cell Stem Cell 11:701-14
Cherry, Anne B C; Daley, George Q (2012) Reprogramming cellular identity for regenerative medicine. Cell 148:1110-22
Robinton, Daisy A; Daley, George Q (2012) The promise of induced pluripotent stem cells in research and therapy. Nature 481:295-305
Zhu, Hao; Lensch, M William; Cahan, Patrick et al. (2011) Investigating monogenic and complex diseases with pluripotent stem cells. Nat Rev Genet 12:266-75
Zhu, Hao; Shyh-Chang, Ng; Segrè, Ayellet V et al. (2011) The Lin28/let-7 axis regulates glucose metabolism. Cell 147:81-94
Kim, Kitai; Zhao, Rui; Doi, Akiko et al. (2011) Donor cell type can influence the epigenome and differentiation potential of human induced pluripotent stem cells. Nat Biotechnol 29:1117-9
Loh, Yuin-Han; Yang, Lin; Yang, Jimmy Chen et al. (2011) Genomic approaches to deconstruct pluripotency. Annu Rev Genomics Hum Genet 12:165-85
Unternaehrer, Juli J; Daley, George Q (2011) Induced pluripotent stem cells for modelling human diseases. Philos Trans R Soc Lond B Biol Sci 366:2274-85
Bandukwala, Hozefa S; Wu, Yongqing; Feuerer, Markus et al. (2011) Structure of a domain-swapped FOXP3 dimer on DNA and its function in regulatory T cells. Immunity 34:479-91

Showing the most recent 10 out of 16 publications